Point-Counterpoint: Cervical Cancer Screening Should Be Done by Primary Human Papillomavirus Testing with Genotyping and Reflex Cytology for Women over the Age of 25 Years.
about
Prevalence of and risk factors for high-risk human papillomavirus infection: a population-based study from Hetian, Xinjiang, China.Primary HPV testing verification: A retrospective ad-hoc analysis of screening algorithms on women doubly tested for cytology and HPV.Human papillomavirus molecular biology.Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway.Clinical validation of the PCR-reverse dot blot human papillomavirus genotyping test in cervical lesions from Chinese women in the Fujian province: a hospital-based population study.Comparison of the performance of Anyplex II HPV HR, the Cobas 4800 human papillomavirus test and Hybrid Capture 2.Discrepant HPV/cytology cotesting results: Are there differences between cytology-negative versus HPV-negative cervical intraepithelial neoplasia?Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy.A prospective pilot evaluation of vaginal and urine self-sampling for the Roche cobas 4800 HPV test for cervical cancer screening.The Next Generation of Cervical Cancer Screening: Should Guidelines Focus on Best Practices for the Future or Current Screening Capacity?
P2860
Q36614232-70D5ED77-01E4-438E-BAD0-46D94D5C2E61Q38823664-48DED7E6-85B7-491F-A3E1-2483028B5FC1Q39320611-A4BD1676-A657-482D-86EC-7ACFEDD68CAAQ40096086-ACCB9BE0-1059-4267-9098-091A99A5AD04Q40155311-8A347106-6472-424C-8213-F0196A369B41Q40943325-23C0A754-5422-4990-A56E-23E26B27E591Q47669409-045A267B-B150-4563-B48D-3CBFB72888BAQ54940603-ACB5A17B-3937-4DE7-BF50-547625271741Q55241245-409F1128-07CA-474A-A2EA-79924A14F454Q55262796-F6EF0FBC-55B9-4FEA-B838-CC0EEC7BD2BC
P2860
Point-Counterpoint: Cervical Cancer Screening Should Be Done by Primary Human Papillomavirus Testing with Genotyping and Reflex Cytology for Women over the Age of 25 Years.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Point-Counterpoint: Cervical C ...... omen over the Age of 25 Years.
@ast
Point-Counterpoint: Cervical C ...... omen over the Age of 25 Years.
@en
type
label
Point-Counterpoint: Cervical C ...... omen over the Age of 25 Years.
@ast
Point-Counterpoint: Cervical C ...... omen over the Age of 25 Years.
@en
prefLabel
Point-Counterpoint: Cervical C ...... omen over the Age of 25 Years.
@ast
Point-Counterpoint: Cervical C ...... omen over the Age of 25 Years.
@en
P2093
P2860
P356
P1476
Point-Counterpoint: Cervical C ...... omen over the Age of 25 Years.
@en
P2093
Chengquan Zhao
Mark H Stoler
R Marshall Austin
P2860
P304
P356
10.1128/JCM.01087-15
P407
P577
2015-05-06T00:00:00Z